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Background/Aim. Most studies of esophageal and gastric adenocarcinomas have shown
a very high rate of p53 gene mutation and/or protein overexpression, but the influence of
the tumour site upon the frequency of p53 protein expression has not been evaluated
(gastroesophageal junction, Barret's esophagus, and antrum). The aim of our study was
to analyze the correlation between the selected clinico-pthological parameters, and p53
protein overexpression in regards to the particular tumour location. Methods. The mate-
rial comprised 66 sugical specimens; 10 were Barrett’s carcinomas, 25 adenocarcinomas
of the gastric cardia (type II adenocarcinoma of the esophagogastric junction – EGJ),
and 31 adenocarcinomas of the antrum. Immunostaining for p53 protein was performed
on formalin-fixed, paraffin-embedded tissue sections, using the alkaline phosphatase –
antialkaline phosphatase (APAAP) method. The cases were considered positive for p53 if
at least 5% of the tumour cells expressed this protein by immunostaining. Results. There
was no significant difference observed between the studied groups in regards to age, sex,
Lauren’s classification
 and tumour differentiation. There was, however, a significant dif-
ference observed in the depth of tumour invasion between Barrrett’s adenocarcinoma
and adenocarcinoma of the cardia compared with the adenocarcinoma of the antrum.
Namely, at the time of surgery, both Barrett’s adenocarcinomas and adenocarcinomas of
the cardia, were significantly more advanced comparing with the adenocarcinomas of the
antrum. Overexpression of p53 was found in 40% (4/10) of Barrett’s adenocarcinomas,
72% (18/25) of adenocarcinoma of the cardia and 65% (20/31) of adenocarcinoma of the
antrum. No significant differences in p53 expression in relation to sex, type (Lauren) of
tumour, depth of invasion, lymph node involvement, or tumour differentiation were ob-
served in any of the analyzed groups of tumours. Patients with more advanced Barrett’s
adenocarcinoma and in the cases of lymph node invasion revealed tendency for the
greater p53 positivity compared with the early forms and lymph node-negative cases;
however, this difference was not significant according to the statistical analysis. With re-
gard to adenocarcinoma of the cardia, higher rates of p53 positivity were recorded in
poorly differentiated, more advanced cases with lymph node invasion. Nevertheless, none
of these differences was statistically significant. On the contrary, in the patients with ade-
nocarcinoma of the antrum, greater p53 positivity was revealed in early forms without
lymph node involvement, but the observed difference was not statistically significant.
Conclusion. No significant differences in p53 protein expression in terms of sex, type
(Lauren) of tumour, depth of invasion, lymph node involvement, or tumour differentiation
were observed in any of the analyzed groups of tumours (Barrett’s adenocarcinoma, ade-
nocarcinoma of the cardia and adenocarcinoma of the antrum).
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Introduction
Gastric adenocarcinomas comprise a heterogenous
group of tumours. They can occur in the antrum, in the gas-
tric body, and at the esophagogastric junction (EGJ). Ade-
nocarcinomas of the gastroesophageal junction have many
features in common with adenocarcinomas of the esopha-
gus. They show a rapidly increasing incidence in most
Western countries, a time trend different from those in the
distal stomach (1, 2). Both are more common in white
males. The ratio of males to females appears to be a little
higher for esophageal than for cardia adenocarcinoma, but
the difference is of no statistical significance. The age of di-
agnosis is similar (60–65 years), with a tendency for adeno-
carcinoma of the EGJ to be diagnosed at a later age. Some
authors have reported differences in risk factors, between
patients with adenocarcinoma of the EGJ and esophageal
adenocarcinoma. There may be a stronger history of smok-
ing and alcohol consumption in patients with adenocarci-
noma of the cardia (3). Most of these tumours are diagnosed
in advanced stages, and the prognosis is worse than that for
carcinomas located in the middle or distal third of the stom-
ach (4, 5).
Esophageal adenocarcionama develops most often on
Barrett’s metaplastic mucosa, a condition that arises in
about 10% of patients with chronic gastro-esophageal reflux
disease. This cancer develops through a histological and
biological sequence from metaplasia to dysplasia and
eventually through carcinoma (6). While the relationship of
the specialized intestinal metaplasia and esophageal adeno-
carcinoma is well recognized (7, 8), the pathogenesis of
specialized intestinal metaplasia in the cardia and its im-
portance in cancerogenesis is still not well defined.
Among the registrated genetic abnormalities in oeso-
phageal and gastric adenocarcinomas, allelic losses on
chromosome 17p and mutation of the p53 gene have been
documented to be frequent events (9–11). p53 is a the tu-
mour-suppressor gene that encodes p53 protein, which al-
lowes necessary DNA repairs by slowing down the cell cy-
cle at the G1-S transition, and suppresses tumour growth by
inducing apoptosis (12). Among the oncogenes and tumour
suppressor genes, p53 is an important one since the muta-
tions of this gene are the most frequent genetic alterations
so far identified in human tumours
 (12, 13). p53 protein ex-
pression, either secondary to mutation or adhesion to other
cellular or viral proteins, can be detected by immunohisto-
chemistry, and therefore, is an indirect way of analyzing the
functional status of p53 gene. As such, the accumulation of
p53 protein may be considered an indicator of p53 mutation
(14). The nuclear accumulation of p53 protein has been de-
tected in a variety of malignant tumours including Barrett’s
adenocarcinoma and gastric cancer and the relationship
between p53 overexpression and poor prognosis has been
reported (9–11, 14).
Most studies of esophageal and gastric adenocarci-
nomas have shown a very high rate of p53 gene mutation
and/or protein overexpression, but the influence of the
tumour site upon the frequency of p53 protein expression
has not been evaluated in most of the published studies.
The aim of our study was to the analyze the correlation
between the selected clinico-pathological parameters and
p53 protein overexpression in regards to particular tumour
location.
Methods
Patients and tissues
The material comprised 66 sugical specimens which
were retrieved from the files of the Department of Histopa-
thology of the First Surgical Clinic of Clinical Center of
Serbia, Belgrade, during a 4-year period (1997–2000). Ten
surgical specimens were collected from the patients with
Barrett’s carcinoma, 25 from the patients operated for ade-
nocarcinoma of the gastric cardia (type II adenocarcinoma
of the EGJ), and 31 surgical specimen from the patients op-
erated for adenocarcinoma of the antrum. Adenocarcinoma
of the cardia was defined as a tumour with a center located
within 2 cm of the esophagogastric junction, with no sur-
rounding metaplastic mucosa detected preoperatively or on
gross examination of the surgical specimen (15). The Lau-
ren’s histological classification of gastric carcinoma (16), as
well as the evaluation of tumour differentiation were per-
formed.
Immunohistochemistry
Immunostaining was performed on formalin-fixed,
paraffin-embedded 5 μm tissue sections, using the alkaline
phosphatase – antialkaline phosphatase (APAAP) method.
The anti-p53 monoclonal antibody (M 7001, DAKO A/S,
Glostrup, Denmark), (dilution 1/10) were also used. The
bridging rabbit antimouse (Z259) (dilution 1/50) and
APAAP complexes (D651) (dilution 1/50) were obtain also
from Dako. A stage of microwave heating in a solution of
sodium citrate (0.1M, pH = 6) was performed prior to incu-
bation with primary antibody.
For negative controls the primary antibody was omit-
ted and for positive controls a Barrett’s adenocarcinoma
with positive immunostaining as well as gastric cardia and
antrum adenocarcinoma were included with each batch.
The cases were considered positive for p53 if at least
5% of the tumour cells expressed this protein by immu-
nostaining. Nuclear expression was considered positive for
p53 and protein immunoexpression was counted in 20 ran-
domly selected fields at ×40 magnification.
Sttistical analysis
Statistical analysis was performed with the SPSS pro-
gram for Windows (6.0, 1993), using the χ
2 test. The
Fisher’s test was used when there were fewer than five
cases in one group included in the table for statistical
evaluation. The results were considered statistically signifi-
cant when p < 0.05.Број 12 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Страна 881
Results
Table 1 shows the major pathological features of re-
sected tumours. There was no significant difference ob-
served between studied groups in regards to age, sex, Lau-
ren’s classification
 and tumour differentiation. There was a
significant difference observed in the depth of tumour inva-
sion between Barrrett’s adenocarcinoma and adenocarci-
noma of the cardia compared to the adenocarcinoma of the
antrum. Namely, at the time of surgery, both Barrett’s ade-
nocarcinomas and adenocarcinomas of the cardia, were sig-
nificantly more advanced comparing to adenocarcinomas of
the antrum.
Table 2 presents the correlation between p53 immuno-
positivity and the different clinico-pathological characteris-
tics in regards to tumour location. p53 overexpression (nu-
clear staining of 5% or more of tumour cells) was found in
40% (4/10) of Barrett’s adenocarcinomas (Figure 1), 72%
(18/25) of cases of adenocarcinoma of the cardia, and 65%
(20/31) of adenocarcinoma of the antrum.
No significant differences in p53 expression in relation
to sex, type (Lauren) of tumour, the depth of invasion, the
lymph node involvement, or the tumour differentiation were
observed in any of the analyzed groups of tumours. Patients
with the more advanced Barrett’s adenocarcinoma and in
the cases of lymph node invasion revealed the tendency for
greater p53 positivity compared with the early forms and
lymph node-negative cases; however, this difference was
not significant according to the statistical analysis. With re-
gard to adenocarcinoma of the cardia, the higher rates of
p53 positivity were recorded in the poorly differentiated,
more advanced cases with lymph node invasion. Neverthe-
Table 1
Major pathological features of the resected tumours
Barrett’s
adenocarcinoma
(n = 10)
Adenocarcinoma
of the cardia
(n = 25)
Adenocarcinoma
of the antrum
(n = 31)
Age 58.89 (44–80) 61.4 (39–72) 56 (31–77)
Sex
Male
Female
9
1
18
0.7
18
13
Lauren
Intestinal
Diffuse
Mixed
9
1
0
18
0.2
0.5
22
07
0.2
Depth
T1, T2
T3, T4
4
  6*
11
  14*
24
    7*
Lymph nodes
Negative
Positive
2
8
0.5
20
4
27
Grade
Well
Moderate
Poor
0
8
2
1
10
14
0.3
0.9
19
*Barrett vs. Antrum p < 0.03; Cardia vs. Antrum p < 0.01
Table 2
Correlation between p53 positivity and the different clinico-pathological characteristics
in regards to the tumour location
Barrett’s adenocarcinoma Adenocarcinoma of the cardia Adenocarcinoma of the antrum
No. of
cases
p53 positive
(%)
No. of
cases
p53 positive
(%)
No. of
cases
p53 positive
(%)
Sex
Male
Female
9
1
33.3
10.0
18
07
66.6
85.7
18
13
77.7
46.2
Lauren
Intestinal
Diffuse
Mixed
9
1
–
44.4
00.0
–
18
02
05
61.1
100.0
100.0
22
7
2
72.7
57.1
0.0
Depth of invasion
T1, T2
T3, T4
4
6
25.0
50.0
11
14
063.6
078.6
24
7
66.7
57.1
Lymph nodes
Negative
Positive
2
8
00.0
50.0
05
20
060.0
075.0
4
27
75.0
62.9
Grade
Well
Moderate
Poor
−
8
2
−
50.0
00.0
01
10
14
00.0
60.0
85.7
03
09
19
66.7
77.7
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less, none of these differences was statistically significant.
On the contrary, in the patients suffering from adenocarci-
noma of the antrum, greater p53 positivity was revealed in
early forms without lymph node involvement, but the ob-
served difference was not statistically significant.
Fig 1. – Overexpression of p53 protein in the well-diferentiated
Barrettis adenocarcinoma (intestinal type) APAAP, ×20
Fig. 2 – Overexpression of p53 protein in the moderately dif-
ferentiated adenocarcinoma of the cardia. APAAP, ×20
Fig. 3 – Overexpression of p53 protein in the well-
differentiated adenocarcinoma of the antrum. APAAP, ×20
Discussion
Over the recent decades, there has been an alarming rise
in the incidence and prevalence of adenocarcinoma of the
esophagogastric junction in the Western world, in contrast
with the decreasing prevalence of gastric cancer. It is the con-
sequence, primarily of an increase in rate of adenocarcinoma
of the distal esophagus. Nevertheless, the incidence of gastric
tumours is shifting from the distal portion of the stomach to
the proximal stomach and the gastric cardia. Adenocarcino-
mas of the esophagus and gastric cardia share similar epide-
miological and pathological features (1, 17).
Some investigators believe that carditis and subse-
quently intestinal metaplasia of the cardiac mucosa are the
consequences of repeated injury of the cardiac epithelium
by gastric and duodenal content, with duodenal components
as the crucial agent (18, 19). The reason why the process is
limited to the cardia in some patients while, in others, it in-
volves the esophagus, is due to the competence of the lower
esophageal sphincter. On the other hand, histologically and
functionally, the antrum and the cardia share similar epithe-
lium (20) with mucus secreting cells and similar local pH
that determines the growth behavior of Helicobacter pylori
(21).
 So, it is not unreasonable to believe that the inflam-
matory changes on those sites can have similar conse-
quences regarding the Helicobacter pylori infection.
Intestinal metaplasia was found in several studies in
the peritumorous mucosa of the gastric cardia tumors, al-
though, it was not always clear whether it has its origin in
esophagus or the proximal stomach (8, 22). Thus, it is be-
lieved that intestinal metaplasia may have a premalignant
potential (23). The pathogenesis of both esophageal and
gastric cardia adenocarcinomas is likely to be associated
with the specialized intestinal metaplasia. While the rela-
tionship of the specialized intestinal metaplasia and eso-
phageal adenocarcinoma is well recognized (7, 8), the
pathogenesis of specialized intestinal metaplasia in the car-
dia and its importance in the cancerogenesis is still not well
defined.
Stein et al. have defined adenocarcinoma of the
esophagogastric junction as tumours which have their center
within 2 cm proximal or distal to the anatomical cardia and
have differentiated three distinct tumour entities within this
area. Barrett’s esophagus with the subsequently developed
dysplastic changes is the main precursor lesion for adeno-
carcinoma in the distal esophagus. Type II and III tumours
may also rise from the so-called short segments of intestinal
metaplasia at or below the cardia, but it happens in less than
40% of patients with carcinoma of the cardia and in less
than 10% of those with subcardial carcinoma. These tu-
mours maybe associated with Helicobacter pylori and in-
testinal metaplasia at or below the gastric cardia contrary to
the specialized intestinal metaplasia in the distal esophagus
that is reflux related (15).
Overexpression of p53 protein is frequently observed
in the dysplastic areas and cancer in Barrett’s esophagus. ItБрој 12 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Страна 883
has been suggested that this is an early event in the dyspla-
sia-carcinoma sequence (6). A number of descriptive mo-
lecular studies in esophageal adenocarcinoma has reported
on frequency of the mutation of the p53 tumour suppressor
gene, and p53 protein overexpression as the most com-
monly described abnormality. The incidence of p53 muta-
tion tended to increase with the progression along the meta-
plasia-dysplasia-carcinoma sequence, with the mutation
being rare in nondysplastic tissue, but present in up to 90%
of esophageal adenocarcinomas (20, 24–26).
On the other hand, stadies of p53 alterations in gastric
cancer have reported a slight lower frequency of either alle-
lic loss on chromosome 17p, p53 gene mutation, or p53
protein overexpression. p53 overexpression has been de-
tected in 26–65% of gastric adenocarcinoma (27, 28). In
most studies, the frequency of p53 protein overexpression
was not compared to the location of the tumours.
We investigated the frequency of p53 protein expres-
sion in a series of Barrett adenocarcinoma, adenocarcinoma
arising in the cardia (type II adenocarcinoma of the esopha-
gogastric junction) and the gastric antrum. We found no as-
sociation between p53 protein overexpression and neither
tumour stage or histological type nor tumour location.
Similar results have been reported in most series of adeno-
carcinomas of the esophagus and stomach (14, 24, 25).
Some studies have shown a higher frequency of p53 altera-
tions in the gastric cancers of the intestinal type (Lauren’s
classification) when compared with the diffuse type (29), a
feature that we were unable to confirm, which might be be-
cause of the relatively small number of cases. Furthermore,
in most studies the frequency of p53 alterations was not
compared with the tumour location. We revealed the ten-
dency for greater p53 positivity in adenocarcinoma of the
cardia and adenocarcinoma of the antrum, than in Barrett’s
adenocarcinoma; the result that is quite opposite to the pre-
vious reports in which greater p53 positivity can be attrib-
utes to a more proximal gastric tumours as well as in Bar-
rett’s adenocarcinoma (6, 11, 27, 30–33). In the compara-
tive study of p53 alterations in the consecutive series of oe-
sophageal and cardia adenocarcinomas, a high frequency of
gene mutation (70% and 63%, respectively), and p53 pro-
tein production (70% and 59%, respectively) was observed
in both groups of tumours. In respect to the anatomical site
of tumours, higher frequency of DNA aneuploidy (34), and
lower frequency of microsatellite instability (32, 35), were
observed in adenocarcinomas of the cardia and the oe-
sophagus when compared with adenocarcinomas of the an-
trum. In our study we found no other site specific differ-
ances.
The observed clinicopathological parameters were not
associated with p53 protein overexpression except at the
time of surgery, Barrett’s adenocarcinomas and adenocarci-
nomas of the cardia, both were more significantly advanced
comparing to adenocarcinomas of the antrum.
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EKOPRESIJA PROTEINA p53 KOD BARRETTOVOG ADENOKARCINOMA I
ADENOKARCINOMA KARDIJE I ANTRUMA
Uvod/Cilj. Veliki broj studija pokazao je da postoji visoka stopa mutacije gena p53
i/ili povećana ekspresija proteina p53 kod adenokarcinoma jednjaka i želuca, ali
mali broj istraživanja je posvećen uporednim proučavanjima p53 na različitim loka-
lizacijama ovih tumora (gastroezofagogastrični spoj, Barrettov ezofagus i antrum).
Zato je cilj ove studije bio proučavanje korelacije između kliničkopatoloških para-
metara i prekomerne ekspresije proteina p53 kod adenokarcinoma na navedenim
lokalizacijama. Metode. Istraživanje je sprovedeno kod 66 bolesnika koji su operi-
sani od Barrettovog adenokarcinoma (n = 10), adenokarcinoma kardije (n = 25, tip
II adenokarcinoma ezofagogastričnog spoja) i adenokarcinoma antruma (n = 31).
Imunohistohemijsko bojenje metodom alkaline phosphatase – antialkaline phosp-
hatase (APAAP) u cilju dokazivanja preterane ekspresije proteina p53 sprovedeno
je na tkivnim presecima hirurških uzoraka tumora fiksiranih u formalinu i ukaluplje-
nih u parafin. Tumori „pozitivni“ na p53 bili su oni kod kojih je više od 5% tumorskih
ćelija pokazalo nukleusno imunohistohemijsko bojenje. Rezultati. Između ispitiva-
nih grupa bolesnika nije bilo razlika u distribuciji u odnosu na godine, pol, tip tumo-
ra po Laurenovoj klasifikaciji, kao i u odnosu na diferentovanost tumora. Međutim,
postojala je značajna razlika u dubini tumorske invazije između Barrettovog adeno-
karcinoma i adenokarcinoma kardije u odnosu na adenokarcinom antruma. Naime,
u momentu hirurške intervencije, stadijum tumorske bolesti bio je značajno veći kod
Barrett-ovog adenokarcinoma i adenokarcinoma kardije u odnosu na adenokarci-
nom antruma. Prekomerna ekspresija proteina p53 nađena je kod 40% (4/10) slu-
čajeva Barrettovog adenokarcinoma, 72% (18/25) slučajeva adenokarcinoma kar-
dije, kao i kod 65% (20/31) bolesnika sa adenokarcinomom antruma. Nije bilo razli-
ka u pogledu ekspresije proteina p53 između ispitanika različitih grupa u odnosu na
ispitivane kliničko-patološke parametre: starost, pol, tip tumora, invazivnosti, za-
hvačenost limfnih nodusa i diferentovanost tumora. Zaključak. Između bolesnika
sa Barrettovim adenokarcinomom, adenocarcinomom kardije i adenokarcinomom
antruma nema razlika u prekomernoj ekspresiji proteina p53 u odnosu na starost,
pol, tip tumora, invazivnosti, zahvačenost limfnih nodusa i diferentovanost tumora.
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